Recursion Pharmaceuticals: The AI-Powered Drug Development Pioneer With a $4 Stock Price

Recursion Pharmaceuticals (RXRX) is developing a platform called Recursion OS that uses artificial intelligence to virtually test drugs, reducing clinical trial costs and time. The company has eight drugs in development, with half in clinical trials. Analysts expect its top line to improve from $62 million in 2022 to $83 million in 2023 and $163 million in 2028. The stock is currently trading at $3.98, up 11.80% today. While there is risk, the AI-powered drug development industry is expected to grow at a 30% annual rate between 2023 and 2034.